The valsartan tablets may contain small amounts of N-nitrosodiethylamine, which is a possible human carcinogen, according to USA Today. The pharmaceutical company has not received any reports of adverse effects linked to the tablets.
Aurobindo is the latest drugmaker to recall the blood pressure drug amid heightened safety concerns over the presence of N-nitrosodiethylamine. Major Pharmaceuticals, Teva Pharmaceuticals and Mylan have also recalled valsartan products in the past year.
To view the FDA’s full recall report, click here.
More articles on pharmacy:
January’s first drug price hikes average 6.3%: 5 notes
Judge blocks Trump administration policy cutting drug payments to hospitals
Biosimilars cost up to 80% more in the US than Europe: Here’s why
